NCT00563225

20 Week Bridging Study in Type II DM

A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus

Conditions

• Diabetes Mellitus Type II

Interventions

Type	Name	Description
DRUG	Insulin Glargine	Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)

Timeline

• Start date: 2002-10-01
• Completion: 2004-04-01
• First posted: 2007-11-26
• Last updated: 2007-11-26